IP Library Granted Patent US 8,100,963
Granted Patent B2
US 8,100,963 · App. 11/646,890 · Granted Jan 24, 2012

Biodegradable device

Assignee: Icon Medical Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,100,963
App. No.
11/646,890
Granted
Jan 24, 2012
Kind
B2
Abstract

A device that is at least partially formed of a biodegradable polymer. The device can be at least partially formed by MEMS technology. The device can include one or more micro-structures that are also formed by MEMS technology. The device can include one or more agents that can be controllably and/or uncontrollably released from the device.

Claims (25)

1. An expandable medical device for insertion in a body passageway that is used in treating dissected blood vessels, vascular malformations, vulnerable plaque by encapsulation, vulnerable plaque by passivation, nerve dissection of the central nervous system, incompetent valves, pulmonary embolism, narrowing of a body passageway, and combinations thereof, said expandable medical device including a body having an unexpanded and expanded cross-section area and a biological agent coated or impregnated on an other surface of said body, majority of said body is formed of a biodegradable polymer system designed to degrade when exposed to fluids in the body passageway so that at least a portion of said body degrades over time and removes itself from a treatment site in said body passageway, a portion of an outer surface of said medical device including a plurality of microstructures that extend upwardly from and above said outer surface of said body, said plurality of microstructures at least partially formed of said biological agent, said plurality of microstructures having a shape and size that is designed to penetrate into said body passageway at the treatment site when said body is expanded to said expanded cross-sectional area and to deliver said biological agent in said penetrated region of said body passageway, said plurality of microstructures having a height of less than 1000 microns.

2. The expandable medical device as defined in claim 1 , wherein said body is in the form of a stent.

3. The expandable medical device as defined in claim 2 , wherein said body is formed of about 100 percent biodegradable material.

4. The expandable medical device as defined in claim 3 , wherein said outer surface of said body including a body coating, said plurality of microstructures extending upwardly from said body coating, said body coating including biodegradable polymer, biological agent, and combinations thereof, said body coating having a different composition from said biodegradable polymer system of said body, said body coating having a thickness of at least about 0.01 μm to less than about less than about 150 μm.

5. The expandable medical device as defined in claim 1 , wherein said body is formed of about 100 percent biodegradable material.

6. The expandable medical device as defined in claim 1 , wherein said outer surface of said body including a body coating, said plurality of microstructures extending upwardly from said body coating, said body coating including biodegradable polymer, biological agent, and combinations thereof, said body coating having a different composition from said biodegradable polymer system of said body, said body coating having a thickness of at least about 0.01 μm to less than about less than about 150 μm.

7. The expandable medical device as defined in claim 6 , including a protective outer polymer coating on said body coating, said protective outer polymer coating including a) one or more polymers selected from the group consisting of parylene, PLGA, PEVA, PBMA, PLA, POE, PGA, PLLA, PAA, PEG and chitosan, b) one or more derivatives of polymers selected from the group consisting of parylene, PLGA, PEVA, PBMA, PLA, POE, PGA, PLLA, PAA, PEG and chitosan, or c) a combination of a) and b).

8. The expandable medical device as defined in claim 6 , wherein said protective outer polymer coating controls a rate of degradation of said biodegradable polymer on said body.

9. The expandable medical device as defined in claim 1 , including a protective outer polymer coating on said plurality of microstructures, said protective outer polymer coating including a biodegradable polymer, said protective coating designed to inhibit or prevent damage to said plurality of microstructures as said body is inserted into said body passageway and to said treatment site, said protective outer polymer coating having a thickness of less than about 300 μm.

10. The expandable medical device as defined in claim 4 , including a protective outer polymer coating on said plurality of microstructures, said protective outer polymer coating including a biodegradable polymer, said protective coating designed to inhibit or prevent damage to said plurality of microstructures as said body is inserted into said body passageway and to said treatment site, said protective outer polymer coating having a thickness of less than about 300 μm.

11. The expandable medical device as defined in claim 10 , including a protective outer polymer coating on said body coating, said protective outer polymer coating including a) one or more polymers selected from the group consisting of parylene, PLGA, PEVA, PBMA, PLA, POE, PGA, PLLA, PAA, PEG and chitosan, b) one or more derivatives of polymers selected from the group consisting of parylene, PLGA, PEVA, PBMA, PLA, POE, PGA, PLLA, PAA, PEG and chitosan, or c) a combination of a) and b).

12. The expandable medical device as defined in claim 11 , wherein said protective outer polymer coating controls a rate of degradation of said biodegradable polymer on said body.

13. The expandable medical device as defined in claim 12 , wherein said agent ranging from about 0.01-100 ug per mm 2 , said agent at least about 0.01 weight percent of the device, and combinations thereof.

14. The expandable medical device as defined in claim 13 , wherein said biological agent is used to promote the growth of an integral endothelial layer.

15. The expandable medical device as defined in claim 14 , wherein said biological agent includes a) one or more agents selected from the group consisting of trapidil, taxol, cytochalasin, paclitaxel, rapamycin, and GM-CSF, b) one or more agents selected from the group consisting of trapidil derivative, taxol derivative, cytochalasin derivative, paclitaxel derivative, rapamycin derivative, and GM-CSF derivative, or c) a combination of a) and b).

16. The expandable medical device as defined in claim 15 , wherein said body includes a plurality of high strain regions when said body is expanded from said unexpanded cross-sectional area and to said expanded cross-sectional area, a plurality of said high strain regions formed of biodegradable material so that such high strain regions degrade at a faster rate as compared to non-high strain regions on said body.

17. The expandable medical device as defined in claim 16 , wherein said body contacts a balloon, a sheath, or combination thereof when inserted in to said body passageway, a plurality of said microstructures deigned to increase retention of said body to said balloon, said sheath, or combinations thereof.

18. The expandable medical device as defined in claim 17 , wherein said biological agent is incorporated into said body.

19. The expandable medical device defined in claim 1 , wherein said agent ranging from about 0.01-100 ug per mm 2 , said agent at least about 0.01 weight percent of the device, and combinations thereof.

20. The expandable medical device as defined in claim 1 , wherein said biological agent is used to promote the growth of an integral endothelial layer.

21. The expandable medical device as defined in claim 1 , wherein said biological agent includes a) one or more agents selected from the group consisting of trapidil, taxol, cytochalasin, paclitaxel, rapamycin, and GM-CSF, b) one or more agents selected from the group consisting of trapidil derivative, taxol derivative, cytochalasin derivative, paclitaxel derivative, rapamycin derivative, and GM-CSF derivative, or c) a combination of a) and b).

22. The expandable medical device as defined in claim 1 , wherein said body includes a plurality of high strain regions when said body is expanded from said unexpanded cross-sectional area and to said expanded cross-sectional area, a plurality of said high strain regions formed of biodegradable material so that such high strain regions degrade at a faster rate as compared to non-high strain regions on said body.

23. The expandable medical device as defined in claim 1 , wherein said body contacts a balloon, a sheath, or combination thereof when inserted in to said body passageway, a plurality of said microstructures deigned to increase retention of said body to said balloon, said sheath, or combinations thereof.

24. The expandable medical device as defined in claim 1 , wherein said biological agent is incorporated into said body.

25. The expandable medical device as defined in claim 1 , wherein said plurality of biodegradable microstructures extend upwardly from said body having a height of at least about 0.01 μm to less than about 300 μm.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2017
From: ICON MEDICAL CORP.
To: MIRUS LLC
Reel/Frame 042481/0825 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2007
From: ROTH, NOAH M.; KONDABATNI, KISHORE; KARNATI, CHANDANA; BRODBECK, WILLIAM
To: ICON MEDICAL CORP.
Reel/Frame 018796/0837 →
Continuity (17)
Continuation In Part 10209591 · Jul 31, 2002
Continuation In Part 10039816 · Oct 26, 2001
Continuation In Part 11646890
Continuation In Part 11283434 · Nov 18, 2005
Continuation In Part 11646890
Continuation In Part 11283330 · Nov 18, 2005
Continuation In Part 11646890
Continuation In Part 11337225 · Jan 20, 2006
Continuation In Part 10209591
Continuation In Part 10039816
Continuation In Part 11646890
Continuation In Part 11283434
Provisional Application 60629397 · Nov 19, 2004
Provisional Application 60658411 · Mar 3, 2005
Provisional Application 60629470 · Nov 19, 2004
Provisional Application 60658374 · Mar 3, 2005
Related Publication 20070123973A1 · May 31, 2007